Bain Capital Life Sciences Investors, LLC's Form 4 filing
Heartflow, Inc. (HTFL) · filed Feb 6, 2026
- Accession no.
- 0001193125-26-041349
- Filed
- Feb 6, 2026, 4:58 PM ET
- Trade date
- Feb 4, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market sales total $56.1M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Bain Capital Life Sciences Investors, LLCCIK 0001703031 | 10% Owner |
| Bain Capital Life Sciences Fund III, L.P.CIK 0001875273 | 10% Owner |
| BCLS Fund III Investments GP, LLCCIK 0001952080 | 10% Owner |
| Bain Capital Life Sciences III General Partner, LLCCIK 0001952106 | 10% Owner |
| BCLS Fund III Investments, LPCIK 0001952107 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 4, 2026 | Common Stock | SSaleDisposed | −2,000,000 | $28.05 | −$56,100,000 | 10,448,158 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.